Showing results (661-670 of 1,351) with videos related to

Sort By:
Pageof 136
Clinical Pharmacology in Drug Development|March 22, 2022
Bioequivalence of Esaxerenone Conventional Tablet and Orally Disintegrating Tablet: Two Single-Dose Crossover Studies in Healthy Japanese MenAkifumi Kurata, Takashi Eto, Junko Tsutsumi, et al.
Clinical Pharmacology in Drug Development|April 12, 2022
Safety, Tolerability, and Pharmacokinetic Evaluation of Single and Multiple Doses of the Dipeptidyl Peptidase 1 Inhibitor Brensocatib in Healthy Japanese and White AdultsHelen Usansky, Esther Yoon, Ariel Teper, et al.
Clinical Pharmacology in Drug Development|May 7, 2019
Evaluation of the Safety, Tolerability, Pharmacokinetics, and Food Effect of Danirixin Hydrobromide Tablets in Japanese Healthy Elderly ParticipantsTakayuki Iida, Yuki Matsuzawa, Hirofumi Ogura, et al.
Clinical Pharmacology in Drug Development|May 16, 2020
Pharmacokinetics and Bioequivalence of 2 Olanzapine Orally Disintegrating Tablet Products in Healthy Chinese Subjects Under Fed and Fasting ConditionsLin Fan, Lizhi Zhang, Hongquan Zheng, et al.
Clinical Pharmacology in Drug Development|May 30, 2020
Bioequivalence Study of 2 Capsule Formulations of Fingolimod 0.5 mg Assessing Both Parent Drug and Active Metabolite in New Zealand Healthy Subjects (Truncated Design)Noelyn Anne Hung, Fernando Guillermo Costa, Cheung-Tak Hung, et al.
Clinical Pharmacology in Drug Development|May 11, 2020
Safety of Candesartan, Amlodipine, and Atorvastatin in Combination: Interaction Study in Healthy SubjectsKristina Gundlach, Katharina Wolf, Isam Salem, et al.
Clinical Pharmacology in Drug Development|September 1, 2021
Assessment of the Effect of Filgotinib on the Pharmacokinetics of Atorvastatin, Pravastatin, and Rosuvastatin in Healthy Adult ParticipantsKacey Anderson, Cara H Nelson, Qi Gong, et al.
Clinical Pharmacology in Drug Development|June 24, 2020
Safety and Pharmacokinetics of High-Dose TAS-303 in Healthy Japanese Volunteers: A Single-Center, Single-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multiple-Ascending-Dose StudyRyuzo Hanada
Clinical Pharmacology in Drug Development|May 4, 2021
A Single Supratherapeutic Dose of Atogepant Does Not Affect Cardiac Repolarization in Healthy Adults: Results From a Randomized, Single-Dose, Phase 1 Crossover TrialRamesh Boinpally, Brian McNamee, Li Yao, et al.
Clinical Pharmacology in Drug Development|June 23, 2020
Pharmacokinetics of Single and Multiple Doses of Omega-3 Carboxylic Acids in Healthy Chinese Subjects: A Phase I, Open-Label StudyShan Jing, Zhenxian Zhang, Xiaowen Chen, et al.
Pageof 136